Payment overview · 2025
General Payments
$382.87
22 reported records · 7 companies
Healthcare provider profile · identity verified
Kelly M Nelson, DO
Allopathic & Osteopathic Physicians|Family Medicine · COEUR D ALENE, ID · NPI 1720293749
Verified facts
What the public records show
CMS Open Payments records show Kelly M Nelson, DO received $382.87 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 39.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $151.70 | 39.6% | 11 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $70.41 | 18.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.83 | 16.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.58 | 8.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.49 | 6.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.94 | 5.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.92 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $382.87 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $70.41 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $63.83 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.83 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $60.00 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.58 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $9.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 148 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
148 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 537 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 411 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 114 |
| Losartan Potassium | Losartan Potassium | 379 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 81 |
| Omeprazole | Omeprazole | 210 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 56 |
| Gabapentin | Gabapentin | 186 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 55 |
| Trazodone Hcl | Trazodone Hcl | 175 | 50 |
| Ozempic | Semaglutide | 148 | 18 |
| Simvastatin | Simvastatin | 144 | 40 |
| Metformin Hcl | Metformin Hcl | 121 | 38 |
| Eliquis | Apixaban | 117 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 35 |
| Sertraline Hcl | Sertraline Hcl | 94 | 23 |
| Synthroid | Levothyroxine Sodium | 93 | 25 |
| Bupropion Xl | Bupropion Hcl | 92 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 41 |
| Meloxicam | Meloxicam | 89 | 25 |
| Mounjaro | Tirzepatide | 89 | 13 |
| Potassium Chloride | Potassium Chloride | 85 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 14 |
| Allopurinol | Allopurinol | 76 | 24 |
| Repatha Sureclick | Evolocumab | 76 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 73 | 25 |
| Alendronate Sodium | Alendronate Sodium | 64 | 17 |
| Farxiga | Dapagliflozin Propanediol | 63 | 17 |
| Jardiance | Empagliflozin | 63 | 15 |
| Montelukast Sodium | Montelukast Sodium | 62 | 18 |
| Furosemide | Furosemide | 60 | 21 |
| Ezetimibe | Ezetimibe | 56 | 18 |
| Buspirone Hcl | Buspirone Hcl | 49 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 13 |
| Tramadol Hcl | Tramadol Hcl | 49 | 15 |
| Valacyclovir | Valacyclovir Hcl | 48 | 21 |
| Atenolol | Atenolol | 47 | suppressed |
| Famotidine | Famotidine | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 46 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | 14 |
| Methocarbamol | Methocarbamol | 37 | 16 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | 11 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Prednisone | Prednisone | 32 | 21 |
| Acyclovir | Acyclovir | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 29 | 29 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 19 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $382.87 · 22 records | Novo Nordisk Inc | JARDIANCE, OTEZLA, Omnipod, Ozempic, REPATHA, REXULTI, The Cologuard Plus Collection Kit, Wegovy, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error